Michael Kavanagh BSc, MBA (Advanced)
CEO, President and Managing Director
Michael joined Nanosonics as CEO and President effective October 2013. He was a Non-executive Director of the Board from July 2012 to October 2013. Michael has more than 25 years of international commercial experience in the healthcare market having held local, regional and global roles in medical device and pharmaceutical industries. Before joining Nanosonics, he was Senior Vice President of Global Marketing for the major medical device company Cochlear Ltd, a position he held for more than 10 years. He has no other current and former directorships in the last three years.
Ron Weinberger BSc (Hons), PhD
President Technology Development/Commercialisation
Ron joined the Company in August 2004 and was appointed as Executive Director in July 2008. From July 2011 to October 2013 he was Managing Director and CEO and since October 2013, he has been President Technology Development/Commercialisation, responsible for the direction of the Company’s technology and the identification of new product and commercial opportunities. Ron has more than 20 years’ experience in medical research and biotechnology and is co-inventor of several of Nanosonics’ key technology patents.
Steven Farrugia, BE, PhD
Senior Vice President, Design and Development
Steven joined Nanosonics as Senior Vice President, Design and Development, in September 2016. He has over 20 years' experience leading the development of medical devices. Prior to Nanosonics, Steven held a range of senior executive roles with ResMed, including VP of Technology and VP of Product Development. He is an inventor of almost 300 granted and pending patents and is an Adjunct Professor of Engineering at The University of Sydney.
McGregor Grant BEc, CA, GAICD
Chief Financial Officer and Company Secretary
McGregor joined Nanosonics in April 2011 and is responsible for the overall financial management of the Company and, together with Michael Kavanagh, has joint responsibility for investor relations. He has more than 21 years’ business experience in a number of senior roles in the medical device and healthcare industries located in Australia and the United States and previously worked for Coopers & Lybrand (now PwC) in Australia and Europe.
Gerard Putt BSc, GAICD
Chief Operations Officer
Gerard joined Nanosonics full time in 2011 after 18 months on the Nanosonics advisory board and has extensive experience in the medical device industry as a leader of development, engineering, production and operations teams. He has particular experience in the implementation of new products into manufacturing and rapid scaling of production to international market needs.
Anthony Harrington BSc, MBA, GAICD
Senior Vice President, Global Marketing
Anthony joined Nanosonics in April 2017. He has more than 25 years’ experience in senior marketing and business development roles in the healthcare sector. This includes seven years at Zimmer in senior regional product marketing management roles.
Anthony has also held executive and non-executive directorship roles, including Managing Director of Biomet ANZ (orthopaedics) and Vice Chairman of the Medical Technology Association of Australia (MTAA).
Ronald J Bacskai BSME, MBA (Hons)
President & CEO, Nanosonics, Inc.
Mr Bacskai joined Nanosonics, Inc. in 2010 and is responsible for leading Nanosonics, Inc. operations in the United States. Mr Bacskai is an experienced executive having worked in multiple industries with a broad technical, marketing and sales, and technology commercialization background. Mr Bacskai has significant experience as President, CEO and board member of several public and private organizations as well as serving on the advisory board of a speciality environmental firm.
Robert J Waring BEc, CA, FCIS, FFin, FAICD
Robert was re-appointed Company Secretary in October 2010 and earlier held this position at the time of the Company’s IPO in May 2007. He is a director of corporate advisory firm, Oakhill Hamilton Pty Ltd, and has had more than 25 years’ experience in Company Secretarial roles for ASX listed companies.